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STEM CELLS IN HEMATOLOGY
SSEA-4 identifies mesenchymal stem cells from bone marrow
Eun J. Gang,1 Darko Bosnakovski,1 Camila A. Figueiredo,1 Jan W. Visser,2 and Rita C. R. Perlingeiro1,2
1Center for Developmental Biology, University of Texas Southwestern Medical Center, Dallas, TX; 2ViaCell, Cambridge, MA
Adult bone marrow (BM) contains hemato-
poietic stem cells (HSCs) as well as a
nonhematopoietic, stromal cell popula-
tion. Within this stromal population are
mesenchymal stem cells (MSCs), which
not only support hematopoiesis but also
differentiate into multiple lineages, includ-
ing fat, bone, and cartilage. Because of
this multipotentiality, the MSC is an attrac-
tive candidate for clinical applications to
repair or regenerate damaged tissues of
mesenchymal origin. However, research
progress has been hampered by the lim-
ited existing knowledge of the biology of
these cells, particularly by the lack of a
suitable marker for their prospective iso-
lation. Here, we report that SSEA-4, an
early embryonic glycolipid antigen com-
monly used as a marker for undifferenti-
ated pluripotent human embryonic stem
cells and cleavage to blastocyst stage
embryos, also identifies the adult mesen-
chymal stem cell population. (Blood. 2007;
109:1743-1751)
© 2007 by The American Society of Hematology
Introduction
Stem cells, which are responsible for maintenance and repair of
most adult tissues, are distinguished by their potential for both
self-renewal and multilineage differentiation. These properties
make stem cells an attractive alternative to treat various degenera-
tive disorders. In adults, a well-known source of stem cells is the
bone marrow (BM) compartment, which contains hematopoietic
stem cells (HSCs) as well as a nonhematopoietic, stromal cell
population. The later, identified as marrow stromal cells or
mesenchymal stem cells (MSCs), not only support hematopoiesis
but also differentiate along various mesodermal lineages to gener-
ate osteoblasts, chondrocytes, and adipocytes.1-3 Because of these
properties, MSCs have been exploited for their potential to repair
or regenerate damaged tissues of mesenchymal origin, including
bone fracture healing,4 tendon repair,5 cartilage regeneration,6,7 and
support of engraftment after chemotherapy.8
One group has also identified a subpopulation of bone marrow–
derived cells, termed multipotent adult progenitor cells (MAPCs),
which possess longer proliferative capacity and broader differentia-
tion potential than MSCs,9,10 including cells of all 3 germ layers in
vitro, as well as the ability to generate chimeric mice when injected
into blastocysts.10 To date, the relation of these cells to MSCs is not
known. It is possible that MAPCs arise in vitro through genetic or
epigenetic changes.
MSCs were first identified more than 20 years ago by Frieden-
stein et al,11-13 who isolated these cells by simply exploiting their
ability to adhere to tissue culture plastic. Despite the enormous
number of studies that have focused on the biology of MSCs in the
past decade, the method for their derivation has not changed much
from their initial identification.1-3,14,15 The caveat of such a method
is heterogeneity of the resulting adherent cells. It is known that
hematopoietic progenitors can persist for a number of weeks in
such cultures, with MSCs comprising a minority of the cell
population.15 Unlike their well-characterized neighbors, the HSCs,
the study of which was revolutionized by methods for prospective
isolation,16-18 a good marker for the purification of the MSCs is
lacking; without prospective isolation and purification it is very
difficult to ascribe any attribute with certainty to the MSC. Once
established in culture, these cells have been reported to express a
variety of cell-lineage–specific antigens, including, among others,
adhesion molecules, integrins, and growth factor receptors2; how-
ever the expression of these markers varies depending on the
culture conditions used.19,20 Moreover, the phenotype of an estab-
lished population of homogenous MSCs is obtained after weeks in
culture, when multilineage potential may be already somewhat
compromised. Thus, such criteria do not necessarily identify MSCs
in their native state; therefore, little progress has been made in their
prospective purification.
Here, we demonstrate that SSEA-4, a stage-specific embryonic
antigen previously thought to mark specifically human embryonic
stem cells and very early cleavage to blastocyst stage embryos, also
identifies an adult mesenchymal stem cell population. We further
show that this marker can be used for the prospective isolation of
MSCs from whole human bone marrow aspirates.
Materials and methods
Animals
Rosa 26-lacZ transgenic and Balb-c mice (both from Jackson Laboratories,
Bar Harbor, ME) were used as BM donors. Rag2/c/ immunodeficient
mice (Taconic Laboratories, Germantown, NY) were used as recipients for
the in vivo bone assay. Animal care and all procedures were performed
according to University of Texas (UT) Southwestern institutional guidelines.
Generation of immortalized mesenchymal stem cell lines
Whole BM was harvested from the femurs and tibias of male Rosa 26-lacZ
transgenic mice after being killed by CO2 inhalation. Cells were plated at
2.4  106/cm2 in the following medium: low-glucose Dulbecco modified
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Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 40%
MCDB-201 (Sigma, St Louis, MO), 10% FBS (Invitrogen), 1  insulin-
transferrin-selenium (ITS; Sigma), 1  linoleic acid-bovine serum albumin
(Sigma), 108 M dexamethasone (Sigma), 104 M ascorbic acid 2-phos-
phate (Sigma), 50 U/mL penicillin/streptomycin, and the following growth
factors: 10 ng/mL hPDGF-BB (R&D Systems, Minneapolis, MN), 10
ng/mL mEGF (Sigma), and 1000 U/mL mLIF (Chemicon, Temecula, CA).
After 3 days of incubation in a humidified incubator at 37°C with 5% CO2,
the nonadherent hematopoietic cells were discarded. The adherent cells
were passaged after a further 2 days of culture in the same medium. Cells
were fed or passaged every 2 days to be kept subconfluent.
BM for mouse primary MSC cultures
Whole BM was flushed from the femurs and tibias of male Balb-c mice with
Iscove modified Dulbecco medium (IMDM; Invitrogen), supplemented
with 5% FBS. In some experiments, to obtain the bone-associated cells,
femurs and tibias were cut into small pieces and crushed using a mortar and
pestle. Bone fragments were treated with 0.2% collagenase (Sigma), gently
agitated for 1.5 hours at 37°C. After the incubation period, the bone-
associated cells were combined with the flushed out cells forming a
single-cell suspension. Cells were plated in the same medium described for
the generation of immortalized MSC lines, at a density of 1.9 106
cells/cm2.After 72 hours, medium and any cells in suspension were aspirated and
replaced with fresh medium. Cultures were passaged every 4 days when
subconfluent (60%-70%) at a cell density of 1.3 to 2 104 cells/cm2.
BM for human primary MSC cultures
Bone marrow samples were obtained from volunteer donors with their
informed consent, under a protocol approved by the Institutional Review
Board of the UT Southwestern Medical Center. In some instances, bone
marrow was purchased from Cambrex (Walkersville, MD). Human MSCs
were isolated from marrow of donors with a modification of Pittenger
protocol.2 Briefly, cells were separated from 20 to 30 mL marrow diluted
with 4 volumes of Minimum Essential Medium Alpha Medium (-MEM;
Invitrogen) containing 10% FBS by centrifugation at 900g for 15 minutes.
Cells were washed with phosphate-buffered saline (PBS) once. Cells were
plated at 2  106 cells/cm2 in expansion medium (low-glucose) DMEM
supplemented with 40% MCDB-201, 10% FBS, 1  ITS, 1  linoleic
acid–bovine serum albumin, 108 M dexamethasone, 104 M ascorbic acid
2-phosphate, 50 U/mL penicillin/streptomycin, 10 ng/mL hPDGF-BB, and
10 ng/mL hEGF. After 72 hours of culture, suspended cells were removed
and replaced with fresh media. Medium was changed every 3 days
thereafter. MSCs grew as colonies which were detached with 0.1%
trypsin-EDTA and subcultured at a density of 4 to 8  103 cells/cm2.
Standardized preparations of hMSCs obtained from the Tulane Center for
Gene Therapy were cultured at a cell density of 100 cells/cm2 in -MEM
containing 16.5% FBS, as recommended.
Flow cytometry and sorting of MSCs
For SSEA-4, SSEA-3, and SSEA-1 antigens, supernatants from the
Developmental Studies Hybridoma Bank (University of Iowa, Iowa City)
were used. The SSEA-4 mouse monoclonal antibody recognizes the
SSEA-4 antigen expressed on human and mouse cells.21 For secondary
staining to this antibody, we used fluorescein-5-isothiocyanate (FITC)–
conjugated goat antimouse. As isotype control, a matching FITC-
conjugated mouse IgG3 antibody (Pharmingen, San Diego, CA) was used.
For secondary staining to SSEA-1 and SSEA-3, we used FITC-conjugated
goat anti–mouse Ig and PE-conjugated goat anti–rat Ig, respectively
(Pharmingen). As matching isotype controls, FITC-conjugated mouse and
rat IgM antibodies were used (for SSEA-1 and SSEA-3, respectively). In
the mouse double-staining experiment, a PE-conjugated anti–SSEA-4
(R&D Systems) and an APC-conjugated anti-CD45 were used.
For the other mouse surface markers, we used PE-conjugated antimouse
antibodies to CD45, Sca-1, c-Kit, and Flk-1 (Pharmingen).
FITC-conjugated antihuman antibody to CD105 (SH2, Endoglin;
Serotec, Raleigh, NC), CD45 as well as PE-conjugated antihuman CD44,
CD73 (SH3), and CD90 (Thy-1) (Pharmingen) were applied for character-
ization of human MSCs.
Adherent cells were collected after a short incubation with trypsin. Cells
were washed twice, first with IMDM 10% FBS and then with blocking
buffer (PBS 1% FBS), suspended in the same buffer containing 0.25 g/106
cells of Fc block (Pharmingen) and placed on ice for 5 minutes. Antibody
was added at 1 g/106 cells and incubated at 4°C for 30 minutes before
washing with blocking buffer, except for staining with the supernatants
from the hybridoma bank (SSEA-1, SSEA-3, and SSEA-4), whereby cells
were resuspended in 100 L supernatant and incubation lasted 40 minutes.
When secondary staining was required, cells were counterstained with
appropriate secondary antibody for 20 minutes at 4°C, followed by washing
with blocking buffer. Stained cells were analyzed on a FACS Aria
cell-sorting system (Becton Dickinson, San Jose, CA) after addition of
propidium iodide (Pharmingen) to exclude dead cells. In the sorting
experiments, MSCs were purified based on the expression of SSEA-4
(positives and negatives). For clonal analysis, SSEA-4 cells were FACS-
deposited into single wells of a 96-well dish. Wells with single MSC
colonies were harvested and expanded into clonal cell lines. These clones
were tested individually for multipotentiality by further subculture in
adipogenic, osteogenic, and chondrogenic media.
Induction protocols
For fat differentiation, cells were plated in the presence of -MEM medium
containing horse serum (12.5%; Invitrogen), FBS (12.5%), penicillin/
streptomycin (50 U/mL), 2-mercaptoethanol (104 M; Sigma), and hydro-
cortisone (104 M; StemCell Technologies, Vancouver, BC, Canada).
Characterization of fat was performed by Oil Red O staining. For
osteogenic differentiation, cells were cultured in the presence of DMEM
medium with fetal calf serum (%), penicillin/streptomycin (50 U/mL),
ascorbate (50 mol/L; Sigma), dexamethasone (0.1 mol/L; Sigma),
-glycerolphosphate (10 mmol/L; Sigma). Characterization was performed
by Alizarin Red S staining, which detects calcium deposition. For chondro-
genesis, cells were cultured as pellets at 3  105 cells/mL in serum-free
chemically defined medium consisting of DMEM (high-glucose), 1 
insulin-transferrin-selenium, 1  linoleic acid–bovine serum albumin,
ascorbate 2-phosphate (50 g/mL), dexamethasone (100 nM), and 10
ng/mL hTGF-1 (R&D Systems). Media was changed every 2 days.
All of the bright-field images were taken on an Olympus IX70
microscope (Olympus Optical, Tokyo, Japan) with a Nikon DXM1200
digital camera (Nikon, Tokyo, Japan) and Nikon ACT-1 software. The
images from immunofluorescent staining were captured with an Olym-
pus BX50 microscope, an Olympus U-CMAD digital camera, and
MetaVue 5.0 software.
In vivo assay for bone formation
MSC cultures initiated with sorted SSEA4 cells from human BM were
transplanted subcutaneously into immunodeficient mice on a hydroxyapatite-
collagen scaffold (Collagraft, NeuColl; Zimmer, Warsaw, IN).22 We used
cells at passage 5 or 8 (2 independent donors). Briefly, cells were
resuspended in 5 mL expansion medium and mixed with scaffold particles
in a 50-mL conical tube at a density of 10  106 cells/cm2 and incubated for
90 minutes at 37°C with slow shaking (60 rpm). Scaffolds loaded with the
cells were immediately implanted into subcutaneous pockets on the dorsal
surface of 10- to 12-week-old male Rag2/c/ mice (n  14). Mice
were anesthetized with a combination of intraperitoneal ketamine (140
mg/kg) and xylazine (7 mg/kg). A total of 12 implants were prepared from
each donor. Each mouse received 3 to 5 implants, always including one
scaffold without cells as a negative control.
Implants were recovered after 4 to 8 weeks, fixed in 4% buffered
paraformaldehyde for 2 days, followed by 1 day in 20% sucrose, and then
frozen in OCT compound. Serial cryosections of entire implants were
analyzed for bone formation. To evaluate tissue morphology, sections were
stained by Hematoxylin and Eosin as well as in 1% Toluidine Blue. Mineral
deposition was detected by von Kossa (3% AgNO3 and contrasting with
Nuclear fast red) and Alizarin Red S staining. Expression of osteocalcin was
analyzed with a specific goat anti–human osteocalcin antibody (Santa Cruz
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Biotechnology, Santa Cruz, CA). Tissue sections were permeabilized with
0.3% triton for 30 minutes, blocked with 10% donkey serum, and incubated
with primary antibody diluted (1:500) in 2% donkey serum/PBS at 4°C
overnight. Cy3 donkey anti–goat IgG (1:800) was used as a secondary
antibody, and DAPI (4,6-diamidino-2-phenylindole) was used to counter-
stain nuclei in the cells.
Reverse transcriptase–polymerase chain reaction
(RT-PCR) analysis
Total RNA was isolated using Trizol (Invitrogen) as recommended by
the manufacturer. First-strand cDNA was produced using Superscript II
reverse transcriptase (Invitrogen) with Oligo dT. Five percent of
first-strand reaction was used for each ensuing PCR reaction. Primer
sequences and PCR conditions are described in Tables 1 and 2 (mouse
and human, respectively).
Results
Clonal mesenchymal stem cell lines from mouse bone marrow
To study the early mesenchymal population present in adult BM,
we cultured mouse BM cells obtained from adult Rosa26-lacZ
transgenic mice in growth medium described for isolation of
MAPCs.9,10 We observed a delayed outgrowth of exponentially
growing populations of cells with spindle-shaped morphology,
indicative of MSCs23 (Figure 1A-B). These cells doubled every
31.5 hours and were maintained in culture for more than 100 days
with no sign of senescence or differentiation. MAPCs have been
reported to express certain pluripotency markers characteristic of
murine embryonic stem (ES) cells, including the transcription
factor Oct-4.10 To determine the relationship between these immor-
talized cell lines and MAPCs, we tested our cells for these markers
as well as other stem cell and lineage-specific antigens. Flow
cytometry analysis revealed that large numbers of cells expressed
high levels of Sca-1 (99.4%), SSEA-4 (71%), and SSEA-3
(34.2%), but all cells were negative for c-Kit, CD45, Flk-1, and
SSEA-1 (Figure 1C). Using real-time PCR, we were unable to
detect Oct-4 expression (data not shown). These results demon-
strate major differences between these cells and MAPCs, which
were reported to be SSEA-1Sca-1lowFlk-1lowCD45c-Kit.10
Furthermore, these cells were single-cell cloned without diffi-
culty at 30 population doublings, by fluorescence-activated cell
sorting (FACS).
A representative clone, B9, was chosen for further characteriza-
tion. The doubling time for this clone was 14.8 hours (Figure 2A),
and, despite the extended time in culture, it had not changed
morphology and still stained positive for LacZ (Figure 2B),
although karyotype analysis revealed various abnormalities, includ-
ing trisomy 1 and 15; monosomy 12, 14, and 17; and translocations
(10 	 8 and 9 	 5). Cell-surface marker analyses (Figure 2C)
demonstrated high levels of expression for Sca-1 (100%), SSEA-3
(88.2%), and SSEA-4 (98.5%). As seen with the bulk (uncloned)
population, clone B9 was negative for CD45, Flk-1, SSEA-1
(Figure 2C), and Oct-4 (data not shown). Analysis of 4 other clones
revealed a similar profile, lack of CD45 and nearly 100% expres-
sion of Sca-1 and SSEA-4 (data not shown). Despite their
karyotypic abnormalities, these cells retained multilineage differen-
tiation potential (Figure 2D). When grown confluent or in media
containing hydrocortisone, B9 cells (as well as other clones)
Table 1. Reverse transcription–polymerase chain reaction mouse primer sequences information
Primer
Primer pair sequence Annealing
temperature, °C
Product
size, bpForward Reverse
-actin GTGGGGCGCCCCAGGCACCA CTCCTTAATGTCACGCACGATTTC 50 520
PPAR-2 GGAGATTCTCCTGTTGACCCAG GGCACTCAATGGCCATGAG 65 403
C/EBP- GATAAAGCCAAACAACGCAACG CTAGAGATCCAGCGACCCGAA 50 253
LPL TTAACTACCCCCTAGACAACGTCCA AAGAGATGAATGGAGCGCTCG 50 388
Adipsin AGACCCCTACCCTTGCAATACG TGTTACCATTTGTGATGTTTTCGATC 50 376
OPN TGGAGATCGAATTCTGCTTG TCAAGTGCTTGAGGGCATAC 50 720
Cbfa-1 AGTAGCCAGGTTCAACGATCTGA GGACCGTCCACTGTCACTTTAATA 50 137
Coll II GGCAACAGCAGGTTCACATA CCACACCAAATTCCTGTTCA 55 166
Agg CTAAGTTCCAGGGTCACTGTTACCG TCCTCTCCGGTGGCAAAGAAGTTG 59 270
Coll X AAGGAGTGCCTGGACACAAT GTCGTAATGCTGCTGCCTAT 55 461
PPAR-2 indicates peroxisome proliferator-activated receptor  2; C/EBP-, CCAAT/enhancer-binding protein-; LPL, lipoprotein lipase; OPN, osteopontin; Cbfa-1,
core-binding factor-1, Coll II, collagen II; Agg, aggrecan; Coll X, collagen X.
Table 2. Reverse transcription–polymerase chain reaction human primer sequences information
Primer
Primer pair sequence Annealing
temperature, °C
Product
size, bpForward Reverse
-actin ACCATGGATGATGATATCGCC GTGCCAGATTTTCTCCATGTC 55 244
PPAR-2 GCTGTTATGGGTGAAACTCT ATAAGGTGGAGATGCAGGCT 55 351
LPL GTCCGTGGCTACCTGTCAT AGCCCTTTCTCAAAGGCTTC 55 717
Adipsin GGTCACCCAAGCAACAAAGT CCTCCTGCGTTCAAGTCATC 55 271
OPN CACATCGGAATGCTCATTGC ATCACCTGTGCCATACCAGT 50 663
Cbfa-1 ACTGGGCCCTTTTTCAGA GCGGAAGCATTCTGGAA 50 317
ALP CTGGTAGGCGATGTCCTTA ACGTGGCTAAGAATGTCATC 50 475
OC CTCACACTCCTCGCCCTA CCTGAAAGCCGATGTGGT 50 262
Coll II TTTCCCAGGTCAAGATGGTC TCACCTGGTTTTCCACCTTC 54 498
Aggrecan TGAGGAGGGCTGGAACAAGTACC GGAGGTGGTAATTGCAGGGAACA 60 350
Coll X GCCCAAGAGGTGCCCCTGGAATAC CCTGAGAAAGAGGAGTGGACATAC 57 703
ALP indicates alkaline phosphatase; OC, osteocalcin.
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differentiated robustly into adipocytes, as demonstrated by Oil Red
O staining and expression of fat-related genes, which are all present
after 5 days of induction (Figure 2D). When exposed to -glycerol-
phosphate, ascorbate, and dexamethasone, calcium deposition was
visible after 2 weeks in culture, which coincided with osteopontin
expression (Figure 2D), indicative of osteoblast differentiation. In
the presence of TGF-, cells differentiated into cartilage as
evidenced by Alcian Blue staining and expression of cartilage-
related genes (Figure 2D). We failed to observe blood or endothe-
lial development in vitro or in vivo when cells were transplanted
into immunodeficient nonobese diabetic/severe combined immuno-
deficient (NOD/SCID) mice (data not shown). These results
suggest that these clones represent immortalized mesenchymal
stem cell lines. The fact that they express very high levels of
SSEA-4 raised the possibility that this antigen, whose expression is
characteristic of human ES cells as well as their malignant
counterparts, embryonic carcinoma (EC) cells,21,24 might also mark
the adult MSC population.
SSEA-4 expression on murine MSCs
To determine whether SSEA-4 expression in these immortalized
MSC lines relates to their transformation or reflects a true property
of MSCs, we evaluated SSEA-4 expression in nontransformed,
primary MSCs. We initially plated mouse bone marrow for
mesenchymal stem cell outgrowth and monitored the expression of
SSEA-4 as well as CD45 (a pan-leukocyte marker). As expected, 2
days after plating the majority of adherent cells were still of
hematopoietic origin (CD45  70%-90%) (Figure 3A-B); how-
ever, we could observe a small population that was positive for
SSEA-4 ( 1%-2%) (Figure 3A-B). As hematopoietic cells were
gradually eliminated from the adherent layer (reduction of CD45),
cells expressing SSEA-4 took over the cultures (Figure 3A-B).
Double-staining analyses revealed an increasing fraction of SSEA-
4CD45 cells (Figure 3A). A SSEA-4CD45 subpopulation also
coexists in these cultures and, although it is increased in the first
few days, it is depleted over time (Figure 3A). We then proceeded
to sort and analyze SSEA-4 and SSEA-4 cells from primary
cultures 2 days after bone marrow was plated for mesenchymal
stem cell growth. When purified cell populations were plated at the
same cell density after sorting, SSEA-4 cells failed to grow,
whereas SSEA-4 cells rapidly adhered to the plastic and produced
a homogeneous cell-monolayer characteristic of MSCs (Figure
3C). When compared with unpurified MSCs, SSEA-4 cells
exhibited superior growth (7.7-fold versus 2.11-fold) after a week
in culture. In one double-staining experiment for SSEA-4 and
CD45, we sorted the 4 cell fractions (SSEA-4CD45, SSEA-
4CD45, SSEA-4CD45, and SSEA-4CD45). MSC growth
was observed only in the SSEA-4CD45 fraction (data not
shown). Flow cytometry analyses revealed that SSEA-4–sorted
cells maintained high levels of SSEA-4 (approximately 90%, 3
days after sort), whereas their unpurified counterparts expressed
only 30% (data not shown). When subjected to specific induction,
sorted SSEA-4 cells gave rise to cells of the adipocytic and
osteoblastic lineages, as observed by appropriate staining and gene
expression analyses (Figure 3D).
Expression of SSEA-4 on human MSCs and their
prospective isolation
Next, we sought to investigate the expression of SSEA-4 in human
bone marrow samples. Approximately 2% to 4% of human BM
Figure 1. Characterization of primitive adherent BM cells. (A)
Growth curve of cells derived from bone marrow (BM) of Rosa
26-LacZ mice; (B) their morphology under an inverted microscope
(original magnification, 10/0.3 NA Ph1), and (C) expression of
surface markers at 39 cell doublings ( 100 days in culture). Histo-
gram profiles are gated on forward and side scatters, and PI-negative
(live) cells are shown in the first 2 panels. Plots show isotype control
staining profile (thin line) versus specific antibody staining profile
(thick line). Percentages represent the fraction of cells that express a
given surface antigen.
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cells are positive for SSEA-4 on day 0 (Figure 4A). These results
were observed in 5 independent BM samples. We then monitored
the expression levels of SSEA-4 in human BM plated in standard
mesenchymal growth conditions (Figure 4A; days 2-21; n  3). As
in the mouse, cells expressing SSEA-4 gradually took over the
cultures (Figure 4A), whereas hematopoietic cells were eliminated
from the adherent layer, as observed by the reduction in CD45
cells (data not shown). High levels of SSEA-4 expression were also
detected in standardized preparations of mesenchymal stem cells
obtained from the Tulane Center for Gene Therapy. Although
robust SSEA-4 expression was evident on human MSCs, levels of
expression were significantly lower than human embryonal carci-
noma (EC) cells (Figure 5). To test whether SSEA-4 expression
could be used for prospective isolation of human mesenchymal
stem cells, we isolated SSEA-4 cells from fresh human bone
marrow. SSEA-4 and SSEA-4 cell populations were sorted from
human bone marrow aspirates and plated at the same cell density
after sorting (performed on 4 independent BM samples). SSEA-4
cells failed to grow, whereas SSEA-4 cells adhered to the plastic
and produced a homogeneous cell-monolayer characteristic of
MSCs (Figure 4B). An equivalent number of unpurified BM cells
plated at the same cell density did not successfully initiate MSC
cultures. Such cultures could only be derived from higher densities
of unpurified cells (data not shown). Growth kinetic analyses
revealed that sorted SSEA-4 BM cells could be grown for more
than 7 weeks without senescence, and that their doubling time was
25.2 hours (Figure 4C). The growth rate remained stable over this
time, as expected for normal primary untransformed cells. To
confirm this, at passage 7 these cells were subjected to karyotype
analysis, which revealed no abnormalities (data not shown).
Flow cytometric analysis of SSEA-4–sorted cells (Figure 4D)
demonstrated the absence of hematopoietic cells in these cultures,
as noted by the lack of CD45, whereas SSEA-4 was maintained at
high levels. When the SSEA-4 fraction from fresh aspirates was
costained with CD45, only the SSEA-4CD45 cell fraction
(representing about 50% of total SSEA-4 cells) grew out (Figure
S1, available on the Blood website; see the Supplemental Figure
link at the top of the online article).
Multilineage differentiation potential of passage 7 SSEA-4
BM cells was also investigated. When exposed to media containing
hydrocortisone, expanded SSEA-4 cells differentiated into adipo-
cytes as demonstrated by Oil Red O staining and expression of
fat-related genes, including PPAR-2 and LPL (Figure 4E, right).
In the presence of media containing TGF-, cells differentiated
toward cartilage, as shown by Alcian Blue staining and expression
of Aggregan and Collagen II, which first appeared at 7 days of
induction (Figure 4E, middle). Differentiation into osteoblasts was
confirmed by the presence of calcium deposition (Alizarin Red S
staining) and expression of bone-associated genes, which were all
present after 11 days in culture (Figure 4E, left).
Figure 2. Characterization of MSC clone B9. (A)
Growth curve of B9 cells obtained by single-cell sorting
from the bulk population at 33 cell doublings. (B) Clonal
cells have similar morphology to the parental population
and stained positive for X-Gal. (C) Flow cytometric
analysis of B9 cells at passage 4. Histogram profiles are
gated on forward and side scatters, and PI negative (live)
cells are shown in the first 2 panels. Plots show isotype
control staining profile (thin line) versus specific antibody
staining profile (thick line). Percentages represent the
fraction of cells that express a given surface antigen. (D)
Multilineage differentiation of clone B9 at passage 18 for
fat (left) demonstrated by Oil Red O staining (top left) and
expression of fat-specific markers in a time-course study
(bottom left); for cartilage (middle) shown by Alcian Blue
staining (top middle) and expression of cartilage markers
(bottom middle); and for bone (right) demonstrated by
Alizarin Red S staining (top right) and expression of
bone-specific genes (bottom right). For panels B and D,
original magnification was 10/0.3 NA Ph1.
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Clonal analysis
To prove conclusively that cultures obtained from SSEA-4–sorted
cells contained true mesenchymal stem cells, as opposed to being
mixed populations of lineage-specific progenitors, we performed
clonal analysis on 2 independent samples. SSEA-4 cells were
sorted from BM and subjected to single-cell cloning by FACS after
2 or more passages (Table 3). We observed, not surprisingly, that
cloning efficiency was superior at lower passages as well as in
medium supplemented with growth factors (PDGF-BB and EGF)
(Table 3). Individual clones were expanded, divided into 3 fractions
each to be evaluated for bone, cartilage, and fat differentiation. The
majority of these clones (76.5%, n  17) differentiated along all 3
induced lineages (Figure 6). This percentage is superior to that
previously described for unpurified MSCs (17% and 34%, with or
without FGF-2, respectively).25
Transplantation of prospectively isolated human MSCs
To demonstrate functional integrity of the MSC population ob-
tained by prospective isolation with SSEA-4, expanded SSEA-4
cells were evaluated for their capacity to produce an organized
bone tissue in vivo (Figure 7). This assay was performed by ectopic
transplantation of expanded SSEA-4 cells (from 2 independent
BM samples) into immunodeficient mice, using hydroxyapatite-
collagen particles as a scaffold.22 Histologic analyses 8 weeks after
transplantation revealed that all of the implants presented an
organized bone tissue as well as contained a network of blood
vessels and fibrous tissue (Figure 7, upper right). Control implants
that received scaffold only (no cells) showed no bone formation,
with only some sporadic cell infiltration (Figure 7, upper left).
Further bone tissue characterization was performed by using
Toluidine Blue (Figure 7, middle, left) for bone structure, and
Alizarin Red S (Figure 7, middle, center), and von Kossa staining
(Figure 7, middle, right), for mineral deposition. Immunofluores-
cence for human-specific osteocalcin (bottom) confirmed the
presence of human cells undergoing bone differentiation. Osteocal-
cin-positive cells were always seen in the vicinity of the scaffold,
the source of calcium and phosphorus for mineralization, as
expected for physiologic bone formation.
Discussion
The results obtained in this study show that SSEA-4, a marker
previously thought to be specific to very early embryonic develop-
ment and to hES cells, also marks an adult mesenchymal stem cell
population and can be used to prospectively isolate MSCs. Such
prospective isolation is particularly attractive as current protocols
used for isolating MSCs2,14,15 or for measuring their frequency
(determined by the number of colony-forming unit fibroblasts;
CFU-Fs)11,26,27 rely simply on their ability to adhere to tissue
culture plastic. This invariably results in heterogeneous cultures.
For instance, it has been shown that some CFU-Fs have a high
ability for self-renewal and multipotentiality, whereas others have
more limited potential,2,27,28 suggesting a high degree of heteroge-
neity within this clonogenic population.14,29 It is also known that
hematopoietic progenitors can persist for a number of weeks in
Figure 3. SSEA-4 marks murine MSCs. Time course for SSEA-4 and CD45 expression in BM adherent cells by flow cytometry. (A) A representative FACS profile of BM
adherent cells analyzed for SSEA-4 and CD45 expression at 2, 4, 7, 14, 21, and 28 days in culture. Fluorescence intensity of SSEA-4 (PE-conjugated) is indicated on
the x-axis, and CD45 (APC-conjugated) is shown on the y-axis. Percentages represent the fraction of cells that express a given surface antigen. (B) SSEA-4 and CD45
expression over time at days 2, 4, 8, 15, and 22. The numbers in parentheses below the bars represent the number of independent bone marrow cultures that were
assayed at that time point. Error bars indicate standard error. (C) Two days after BM was harvested, adherent BM cells were sorted for SSEA4. Although SSEA4 and
SSEA-4 cells were plated at the same cell density, SSEA-4 cells failed to grow (left), whereas SSEA4 cells demonstrated extensive growth (right). (D) Expanded
SSEA4 cells were capable of differentiating along fat and bone lineages when induced with appropriate media, as observed by Oil Red O (top left) and Alizarin Red S
staining (top right), respectively, as well as by gene expression analyses (shown below). Original magnification for panels C and D, 10/0.3 NA Ph1.
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such cultures, with MSCs comprising a minority of the cell
population.15 Furthermore, up to 30%1 or even more (C.A.F. and
R.C.R.P., unpublished data, October 2004) of the cells that arise under
CFU-F growth conditions are hematopoietic as evidenced by CD45
expression. Such heterogeneous cell preparations are far from ideal if
one envisions the use of MSCs for regenerative medicine.
Attempts to obtain a pure population of MSCs have been made
by several groups. For instance, a monoclonal antibody that binds
to stromal cells, named Stro-1, has been produced.30 Although the
surface antigen is still unknown, enrichment for clonogenic stromal
cells (CFU-Fs) has been obtained with the use of this antibody
(Stro-1bright).27 Unfortunately, Stro-1 is also present, at low levels,
on hematopoietic cells (Stro-1dull).27 In the 14 years since Stro-1’s
discovery, no consensus has emerged regarding its use to purify
MSCs. This is due particularly to the fact that other investigators
have failed to detect this antigen on MSCs23 (and our observations).
Another group has reported that human MSCs can be isolated
based on the expression of CD49a, the 1-integrin subunit of the
very late antigen (VLA-1), which is a receptor for collagen and
laminin.26 According to the researchers, this population is
CD49aCD45med/low and contains all CFU-F progenitors present in
the BM fraction. However, this population is heterogeneous and
still contains many hematopoietic cells, not surprising because
CFU-Fs represent a mixed-cell population with CD45 positivity. In
Figure 4. SSEA-4 can be used to prospectively isolate human MSCs. (A) A representative FACS profile of time course analyses of SSEA-4 expression in fresh unsorted
human BM (D0) and adherent cells at 2, 4, 7, 14, and 21 days in culture. Fluorescence intensity of FITC-labeled SSEA-4 is indicated on the x-axis. Percentages represent the
fraction of cells that express SSEA-4 (background is subtracted). The y-axis represents PE, which provides a measure of autofluorescence. (B) Fresh BM was sorted based on
SSEA-4 expression. SSEA4 and SSEA-4 cells were plated at the same cell density (3  104 cells/cm2). SSEA-4 cells failed to grow (left), whereas SSEA4 cells
demonstrated extensive growth (right). (C) Growth curve of SSEA-4 cells sorted on day 0 and plated at 6.3  104 cells. (D) SSEA-4 and CD45 expression on SSEA-4–sorted
cells at passage 2. (E) After appropriate induction, day-0 sorted SSEA4cells were capable of differentiating along fat (left), cartilage (middle), and bone (right) lineages, as
observed by Oil Red O, Alcian Blue, and Alizarin Red S staining, respectively (top row), as well as by relevant gene expression analyses (bottom row). Gene expression for
unrelated lineages (controls) is shown below. Original magnification for panels B and E, 10/0.3 NA Ph1.
Figure 5. SSEA-4 levels in established human MSCs. Flow cytometry analyses of
SSEA-4 expression in (A) standardized preparations of mesenchymal stem cells
obtained from the Tulane Center for Gene Therapy at different passages and (B)
reference controls for levels of expression; EC cell lines, N-TERA-2 and TERA-1 and
3T3 fibroblasts. Fluorescence intensity of SSEA-4 is observed in the x-axis.
Percentages represent the fraction of cells that express SSEA-4. The y-axis
represents PE, which provides a measure of autofluorescence.
Table 3. Cloning efficiency of SSEA-4 MSC cultures
Sample
Growth factors,
PDGF-BB and EGF (%)
No growth factors
(%) Total
BM1 - p2 58/96 (60.4) 33/96 (34.4) 91/192 (47.4)
BM2 - p3 81/192 (42.2) 64/288 (22.2) 145/480 (30.2)
BM2 - p5 51/288 (17.7) 36/384 (9.4) 87/672 (13)
The number of wells with growth out of the total number of wells plated is
indicated. Cloning efficiency, expressed as percentage, is shown in parentheses.
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contrast, SSEA-4 is expressed on both primary MSCs and MSC
lines and, when used for prospective isolation, completely excludes
the hematopoietic population.
The SSEA-3 and SSEA-4 antibodies were raised against
preimplantation murine embryos and human teratocarcinoma cells,
respectively.21,31 Their antigens have been characterized as overlap-
ping carbohydrate epitopes on globo-series glycolipids.21 Their
expression is restricted to preimplantation embryos because a
switch from globo-series to lacto-series (identified by SSEA-1)
synthesis occurs as the blastocyst develops.21,24 Human ES cell
lines retain the earlier globo-series pathway and are SSEA-3/
4SSEA-1,24 whereas mouse ES cell lines use the lacto-series
pathway and are thus SSEA-3/4SSEA-1.24 With the exception of
certain highly specialized cell types (erythrocytes, hence the 4%
expression found in primary human BM, and certain neural
ganglion cells),21,31,32 the globo-series ganglioside synthesis path-
way has been thought restricted to the preimplantation embryo and
not available to somatic cell types.21,31 Although the function of
these carbohydrate antigens is still unknown, it is intriguing that in
addition to pluripotent human ES and EC cells, they also present on
the surface of multipotent MSCs. Although the evidence associat-
ing these markers with a “stemness” state is correlative, it suggests
Figure 6. Clonal multipotentiality of SSEA-4 cells.
Multilineage differentiation of a representative mesenchy-
mal stem cell clone obtained from SSEA4 cells isolated
from human BM aspirates. Fat (A), bone (B), and carti-
lage (C) differentiation were observed by Oil Red O,
Alizarin Red S, and Alcian Blue staining (top), respec-
tively, as well as by relevant gene expression analyses
(bottom). Original magnification, 10/0.3 NA Ph1.
Figure 7. In vivo bone formation by prospectively
isolated human MSCs. Tissue sections from a represen-
tative transplant, stained as indicated, are shown. HA
indicates hydroxyapatite scaffold. For each panel, black
arrows indicate new bone formation; white arrows, fi-
brous tissue. The lower 3 panels show immunohistochem-
istry for human osteocalcin (OC) in red and nuclear
staining with DAPI in blue. Original magnification: 10/
0.3 NA Ph1 (top 2 panels), 20/0.4 NA Ph1 (lower
panels).
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some overlap in specialized metabolic pathways between pluri-
potent human ES cells and multipotent MSCs. Regardless of its
function, the fact that SSEA-4 is present on the surface of MSCs
from human BM aspirates provides a scientific rationale for
their purification. Homogeneous MSC preparations should re-
sult in less variability and superior biologic effects, benefiting
future clinical applications.
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